Orexigen

Orexigen’s Weight-Loss Roller Coaster to End With a Bankruptcy Sale
Orexigen’s Weight-Loss Roller Coaster to End With a Bankruptcy Sale
Xconomy
Orexigen
bankruptcy
Contrave
Flag link:
Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns
Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns
Endpoints
Orexigen
Contrave
M&A
Flag link:
Orexigen - Contrave Sales Present Troubling Data
Orexigen - Contrave Sales Present Troubling Data
Seeking Alpha
Orexigen
Contrave
obesity
Flag link:
Orexigen struggles to stay afloat as obesity market stagnates
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Orexigen
obesity
Contrave
Vivus
Qsymia
Takeda
Flag link:
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Flag link:
Orexigen Therapeutics posts 1st-quarter loss of $22.3 million
Orexigen Therapeutics posts 1st-quarter loss of $22.3 million
Yahoo/AP
Orexigen
earnings
Flag link:
Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial
Orexigen Pulls The Plug On Post-Marketing Cardiovascular Trial
Seeking Alpha
Orexigen
Contrave
Flag link:
Orexigen: Contrave Sales Flatten Out At End Of Q1
Orexigen: Contrave Sales Flatten Out At End Of Q1
Seeking Alpha
Orexigen
Contrave
obesity
Novo Nordisk
Vivus
Arena Pharmaceuticals
Flag link:
Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant
Orexigen buys U.S. obesity pill rights from Takeda, partners Valeant
Yahoo/Reuters
Orexigen
obesity
Contrave
Takeda
Valeant Pharmaceuticals
M&A
Flag link:
Orexigen takes another body blow from ill-fated Contrave trial
Orexigen takes another body blow from ill-fated Contrave trial
Fierce Pharma
Orexigen
Contrave
obesity
Takeda
clinical trials
Flag link:
The Next 6 Months Are Critical For Orexigen
The Next 6 Months Are Critical For Orexigen
Seeking Alpha
Orexigen
Flag link:
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Fierce Pharma Marketing
obesity
Vivus
Orexigen
Contrave
Qsymia
Takeda
Flag link:
Belviq Sales Close Out 2015 With A Slump
Belviq Sales Close Out 2015 With A Slump
Seeking Alpha
Belviq
Arena Pharmaceuticals
obesity
Vivus
Orexigen
Flag link:
Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says
Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says
Fierce Pharma Marketing
Takeda
Contrave
drug reps
Orexigen
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
Contrave script growth snags, despite Takeda's 900-strong salesforce
Contrave script growth snags, despite Takeda's 900-strong salesforce
Fierce Pharma Marketing
Contrave
Takeda
Orexigen
obesity
Flag link:
Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?
Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?
Motley Fool
Orexigen
Europe
drug launches
obesity
Mysimba
Contrave
Flag link:
Orexigen Therapeutics reports second-quarter loss, misses expectations
Orexigen Therapeutics reports second-quarter loss, misses expectations
Yahoo/AP
Orexigen
earnings
Flag link:
Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed
Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed
Seeking Alpha
Orexigen
Contrave
obesity
Arena Pharmaceuticals
Vivus
Flag link:
Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap
Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap
Fierce Pharma Marketing
obesity
Takeda
Contrave
Orexigen
Vivus
Qsymia
Eisai
Belviq
Arena Pharmaceuticals
Flag link:

Pages